Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6528
    +0.0028 (+0.43%)
     

  • OIL

    82.93
    +0.12 (+0.14%)
     

  • GOLD

    2,338.00
    -0.40 (-0.02%)
     

  • Bitcoin AUD

    97,493.06
    -4,177.36 (-4.11%)
     

  • CMC Crypto 200

    1,350.43
    -32.15 (-2.33%)
     

  • AUD/EUR

    0.6085
    +0.0015 (+0.24%)
     

  • AUD/NZD

    1.0954
    +0.0012 (+0.11%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,094.51
    +54.13 (+0.67%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,977.67
    -111.03 (-0.61%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Twist Bioscience to Present at ITF World 2023

Business Wire
·1-min read

SOUTH SAN FRANCISCO, Calif., May 10, 2023--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at Imec Technology Forum (ITF) World 2023 in Antwerp, Belgium on Wednesday, May 17th at 11:10 AM CEST.

The conference brings together different industry leaders to connect on semiconductor advances and deep-tech solutions. Dr. Leproust’s presentation, "Scaling SemiSynBio to fuel the growth towards a $1T semiconductor industry," will discuss how industry growth could be fueled by using CMOS-based chips for high-density DNA synthesis for data storage applications.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

ADVERTISEMENT

Follow us on Twitter | Facebook | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005333/en/

Contacts

For Twist Bioscience:
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com